MarketCap
Facebook
X
Telegram
Tenax Therapeutics Retained Earnings | TENX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -367 M | -315 M | -297 M | -290 M | -278 M | - | -236 M | -228 M | -213 M | -205 M | -151 M | -137 M | -117 M | -108 M | -91.9 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -91.9 M | -367 M | -217 M |
Quarterly Retained Earnings Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -401 M | -383 M | -352 M | -336 M | -325 M | -315 M | -309 M | -305 M | -301 M | -297 M | -294 M | -292 M | -291 M | -290 M | -287 M | -284 M | -281 M | -278 M | -275 M | -271 M | -270 M | -246 M | -246 M | -246 M | -246 M | -236 M | -236 M | -236 M | -236 M | -228 M | -228 M | -228 M | -228 M | -213 M | -213 M | -213 M | -213 M | -205 M | -205 M | -205 M | -205 M | -161 M | -161 M | -161 M | -161 M | -126 M | -143 M | -139 M | -137 M | -115 M | -123 M | -119 M | -117 M | -105 M | -113 M | -111 M | -108 M | - | -97.7 M | -94.8 M | -91.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -91.9 M | -401 M | -222 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M |  USA |
 |
Seagen
SGEN
|
-2.15 B | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-572 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-362 M | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-198 M | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
-486 M | - | - | $ 591 K |  Irlanda |
 |
Spectrum Pharmaceuticals
SPPI
|
-1.12 B | - | - | $ 189 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-256 M | - | - | $ 2.17 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-349 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
-1.69 B | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
-82.3 M | - | -8.77 % | $ 12.4 M |  Israel |
 |
C4 Therapeutics
CCCC
|
-739 M | $ 2.98 | -2.78 % | $ 247 M | USA |
 |
Histogen
HSTO
|
-88.3 M | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
-2.88 B | - | -7.23 % | $ 13 M | USA |
 |
Kaleido Biosciences
KLDO
|
-364 M | - | -3.69 % | $ 12.4 M | USA |
 |
VBI Vaccines
VBIV
|
-582 M | - | -50.87 % | $ 1.09 M | USA |
 |
Certara
CERT
|
-130 M | $ 10.61 | 2.66 % | $ 1.7 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
-2.52 B | - | - | $ 1.2 B | USA |
 |
Decibel Therapeutics
DBTX
|
-278 M | - | - | $ 123 M | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
-392 M | - | 7.4 % | $ 6.29 M | USA |
 |
Provention Bio
PRVB
|
-406 M | - | - | $ 2.37 B | USA |
 |
IVERIC bio
ISEE
|
-865 M | - | - | $ 5.51 B | USA |
 |
Reata Pharmaceuticals
RETA
|
-1.57 B | - | - | $ 6.29 B | USA |
 |
ObsEva SA
OBSV
|
-379 M | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
PolarityTE
PTE
|
-516 M | - | -0.82 % | $ 1.78 M | USA |
 |
Kronos Bio
KRON
|
-595 M | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
-155 M | - | 0.58 % | $ 144 M | USA |
 |
Myovant Sciences Ltd.
MYOV
|
-1.25 B | - | -0.04 % | $ 2.62 B | USA |
 |
Poseida Therapeutics
PSTX
|
-594 M | - | - | $ 857 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
 |
Trevena
TRVN
|
-588 M | - | -46.58 % | $ 31.8 M | USA |
 |
Virpax Pharmaceuticals
VRPX
|
-71.6 M | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
-272 M | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
-487 M | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
-388 M | - | -2.99 % | $ 2.47 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-608 M | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
-212 M | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-382 M | $ 1.29 | -3.38 % | $ 110 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
-1.15 B | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
-183 M | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
-517 M | - | -0.13 % | $ 3.73 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
-856 M | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-286 M | - | 31.87 % | $ 1.61 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |